Wells Fargo & Company MN Raises Stock Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Wells Fargo & Company MN lifted its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 14.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 72,084 shares of the biotechnology company’s stock after acquiring an additional 8,996 shares during the period. Wells Fargo & Company MN owned 0.05% of Aurinia Pharmaceuticals worth $647,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. Arrowstreet Capital Limited Partnership acquired a new position in Aurinia Pharmaceuticals in the 4th quarter valued at about $9,662,000. JPMorgan Chase & Co. grew its stake in shares of Aurinia Pharmaceuticals by 84.4% in the 4th quarter. JPMorgan Chase & Co. now owns 927,298 shares of the biotechnology company’s stock valued at $8,327,000 after purchasing an additional 424,482 shares during the last quarter. Barclays PLC increased its holdings in shares of Aurinia Pharmaceuticals by 187.6% in the third quarter. Barclays PLC now owns 219,331 shares of the biotechnology company’s stock valued at $1,607,000 after purchasing an additional 143,072 shares during the period. Vanguard Group Inc. raised its stake in shares of Aurinia Pharmaceuticals by 6.9% during the fourth quarter. Vanguard Group Inc. now owns 1,729,948 shares of the biotechnology company’s stock worth $15,535,000 after purchasing an additional 112,113 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Aurinia Pharmaceuticals by 22.5% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 556,454 shares of the biotechnology company’s stock worth $4,997,000 after purchasing an additional 102,195 shares during the last quarter. 36.83% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, StockNews.com raised shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 27th.

Aurinia Pharmaceuticals Price Performance

Shares of AUPH opened at $8.20 on Friday. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. The stock’s 50 day moving average is $8.02 and its two-hundred day moving average is $8.17. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.99 and a twelve month high of $10.67. The firm has a market capitalization of $1.12 billion, a PE ratio of -54.66 and a beta of 1.20.

Insider Activity

In related news, insider Greg Keenan sold 12,239 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $97,912.00. Following the completion of the sale, the insider now owns 161,789 shares in the company, valued at $1,294,312. This trade represents a 7.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Peter Greenleaf sold 195,593 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the sale, the chief executive officer now directly owns 1,953,892 shares in the company, valued at approximately $15,631,136. This represents a 9.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 343,898 shares of company stock valued at $2,753,094 in the last three months. 4.30% of the stock is currently owned by company insiders.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.